Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EEF2K | O00418 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18992936 | 0.82 | EEF2K (0.52) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL9655489 | 0.81 | EEF2K (0.47) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL17499950 | 0.77 | EEF2K (0.47) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL14179706 | 0.74 | PTPN1 (0.40) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL14179694 | 0.74 | PTPN1 (0.44) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL14179705 | 0.74 | PTPN1 (0.40) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL11602759 | 0.70 | PLK1 (0.75) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL28371005 | 0.67 | EEF2K (0.34) | EEF2KPLK1PLK2 | |
| SCHEMBL11429279 | 0.67 | PLK1 (0.45) | EEF2KPLK1PLK2PTPN1HIF1A | |
| SCHEMBL18235046 | 0.67 | EEF2K (0.36) | EEF2KPLK1PLK2PTPN1CDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1933821-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | Edison Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035496-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035496-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ECHS1 | EEF2K 922/4885PLK1 3047/4885PLK2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.